Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Search
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Our Twitter Community Guidelines
Our Twitter Community Guidelines
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
Moving towards a rabies-free Southeast Asia
Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
European Metacam® indication expanded to guinea pigs
Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
Partnership with IBM to accelerate new antibody therapies
Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
Boehringer Ingelheim Ruminant Well-Being Awards 2020
The World Association for Buiatrics and Boehringer Ingelheim announce the Ruminant Well-Being Awards.
Boehringer Ingelheim opens Health Management Centre in China
Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Larry’s Story: Advocating for people with lung cancer
In 2013, Larry was diagnosed with non-small cell lung cancer. Learn how his diagnosis led him on a journey of patient advocacy for others with cancer.
GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA
Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
The GPP Forum Report
The generalized pustular psoriasis (GPP) Forum Report summarizes and highlights the important moments form the multistakeholder GPP Forum
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
World Water Day: Good Health Hinges on Good Water
Clean, safe and accessible water is the most basic prerequisite for life and health
Generalized pustular psoriasis (GPP): a chronic inflammatory disease
Learn more about this chronic inflammatory disease associated with skin and systemic symptoms
Are you missing the bigger picture on mental health?
Revolutionizing our approach to serious mental health conditions is crucial for tailored care, placing those with lived experience at the center.
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Partnership African animal trypanosomiasis
New partnership working on solutions to combat African animal trypanosomiasis
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Data Science
Revolutionizing research and development with data driven insights
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines